Preclinical testing of three south American antivenoms against the venoms of five medically-important Peruvian snake venoms

G. D. Laing, A. Yarleque, A. Marcelo, E. Rodriguez, D. A. Warrell, R. D.G. Theakston

Resultado de la investigación: Contribución a una revistaArtículorevisión exhaustiva

19 Citas (Scopus)

Resumen

World Health Organization (WHO)-recommended preclinical in vivo and in vitro studies were carried out to compare the efficacy of Brazilian, Peruvian and Colombian antivenoms in neutralizing the venom toxins responsible for the lethal, haemorrhagic, necrotizing, coagulant and defibrinogenating effects of five medically-important Peruvian snake venoms. Overall, the Brazilian antivenom was found to be the most effective followed by the Peruvian and Colombian antivenoms. However, it was concluded that all three antivenoms would be acceptable for use in a randomised clinical trial in envenomed humans in Peru.

Idioma originalInglés
Páginas (desde-hasta)103-106
Número de páginas4
PublicaciónToxicon
Volumen44
N.º1
DOI
EstadoPublicada - jul. 2004

Huella

Profundice en los temas de investigación de 'Preclinical testing of three south American antivenoms against the venoms of five medically-important Peruvian snake venoms'. En conjunto forman una huella única.

Citar esto